Print Page  Close Window    

StemCells, Inc. to Participate at the Inaugural World Medical Innovation Forum
CEO Martin McGlynn Will Participate on the "Regeneration, Cell Therapy, and Neurocare: Products? Delivery?" Panel

NEWARK, Calif., April 27, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn, CEO of StemCells, Inc., will participate on a panel moderated by Alice Park, writer for TIME Magazine, at the inaugural World Medical Innovation Forum to be held in Boston, April 27-29, 2015. The expert panel members will discuss central nervous system therapies that use healthy cells, tissues or organs—or those created with 3D bioprinters—to replace damaged ones. The panel is scheduled for 9:25 a.m. EDT on Tuesday, April 28, in the Biogen Ballroom at The Westin Copley Place, 10 Huntington Ave, Boston.

About World Medical Innovation Forum Neurosciences

The World Medical Innovation Forum features CEOs of industry-leading multinational medical companies, Partners HealthCare top clinicians and scientists—all Harvard Medical School faculty members—and global technology leaders. Join 1,000 international innovation decision-makers and be briefed on the state of the art in neuroscience technology, care and research directly from the CEOs bringing game-changing products to market, world-class clinicians delivering the highest-quality care and the scientists rapidly propelling this crucial field forward through their CNS insights and discoveries. Additionally, the industry-wide issues driving investment, application and reimbursement of innovation during this period of profound transformation in healthcare will be debated.

The inaugural World Medical Innovation Forum will be held in Boston April 27-29, 2015. Current and emerging approaches to diagnosing and caring for neurologic and psychiatric disorders will be highlighted, including multiple sclerosis, Alzheimer's disease, Parkinson's disease, depression, schizophrenia, autism, stroke and sleep disorders. Also, game-changing diagnostic tools and therapeutic interventions will be presented, including genome editing, gene therapy, neurostimulation, neuroregeneration, population management, neuroimaging and novel biomarkers.

The World Forum is organized around one clinical field per year—neurosciences in 2015 followed by cancer in 2016. The annual Forum provides attendees and policy makers with actionable insights into the torrent of new technology in the neurosciences and the swiftly evolving business of health care innovation. Attendees are senior executives of large companies, investors, entrepreneurs and officers of venture-backed companies, business-minded clinicians and investigators, government principals and dealmakers. Participants include a significant complement of international leaders and organizations.

About StemCells, Inc.

StemCells, Inc. is currently engaged in clinical development of its HuCNS-SC (purified human neural stem cells) platform technology, as a potential treatment for diseases and disorders of the central nervous system. Interim data from the Company's Phase I/II clinical trial in thoracic spinal cord injury (SCI) shows measurable gains involving multiple sensory modalities and segments in half of the subjects, two of whom converted from complete injury (AIS A) to incomplete injury (AIS B), post-transplant. Enrollment has recently commenced in the Company's Phase II clinical trial in cervical SCI. StemCells, Inc. has also completed enrollment and treatment in its Phase I/II clinical trial in geographic atrophy of age-related macular degeneration (GA-AMD), the most severe form of dry AMD, which is the leading cause of blindness in the elderly. Interim results for those subjects with 12 month follow-up post transplantation of HuCNS-SC cells into the eye, showed a reduction in the rate of disease progression as compared to the control (untreated) eye and to the expected natural history of the disease. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company showed preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. Further information about StemCells, Inc. is available at

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 and in its subsequent reports on Forms 10-Q and 8-K.

CONTACT: Greg Schiffman
         StemCells, Inc.
         Chief Financial Officer
         (510) 456-4128

         Lena Evans
         Russo Partners
         (212) 845-4262

company logo

StemCells, Inc.